Literature DB >> 10346415

Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees.

H T Hatoum1, S X Kong, C M Kania, J M Wong, W B Mendelson.   

Abstract

OBJECTIVE: Insomnia is a prevalent sleep complaint which has been reported to be greatly associated with reduced health-related quality of life (HR-QOL) and increased healthcare resource use. This study documents the prevalence of insomnia, and its impact on patients' HR-QOL and healthcare resource use in managed-care settings in the US. DESIGN AND
SETTING: A multi-site survey of 5 American Medical Group Association (AMGA) clinics was conducted. Each clinic mailed questionnaires to 1100 randomly selected individuals enrolled in its healthcare system and distributed questionnaires to 400 individuals during a clinic visit and prior to seeing a physician. The questionnaire was a form of the Health Status Questionnaire with the well-validated Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, a 3-question depression screen, a sleep questionnaire, demographic variables, and questions about medical encounters and prescription and over-the-counter (OTC) drug use. MAIN OUTCOME MEASURES AND
RESULTS: Approximately one-third of managed-care enrollees in this study reported insomnia with daytime dysfunction. Individuals with insomnia reported lower HR-QOL scores and increased healthcare resource use compared with individuals with no insomnia. After controlling for demographic variable and comorbid conditions, the negative association of insomnia remained significant on all HR-QOL scores, emergency room visits, calls to the physician and OTC drug use.
CONCLUSIONS: Insomnia is significantly associated with reduced HR-QOL and increased healthcare resource use in enrollees of managed-care organisations.

Entities:  

Mesh:

Year:  1998        PMID: 10346415     DOI: 10.2165/00019053-199814060-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  8 in total

1.  Prevalence, burden, and treatment of insomnia in primary care.

Authors:  G E Simon; M VonKorff
Journal:  Am J Psychiatry       Date:  1997-10       Impact factor: 18.112

Review 2.  The socioeconomic impact of insomnia. An overview.

Authors:  L A Chilcott; C M Shapiro
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

3.  Sleep disturbance. A component of health status.

Authors:  P Marquis
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

4.  Prevalence of insomnia: a survey of the enrollees at five managed care organizations.

Authors:  H T Hatoum; C M Kania; S X Kong; J M Wong; W B Mendelson
Journal:  Am J Manag Care       Date:  1998-01       Impact factor: 2.229

5.  Prevalence of sleep disorders in the Los Angeles metropolitan area.

Authors:  E O Bixler; A Kales; C R Soldatos; J D Kales; S Healey
Journal:  Am J Psychiatry       Date:  1979-10       Impact factor: 18.112

6.  Sleep problems and their correlates in a working population.

Authors:  M Kuppermann; D P Lubeck; P D Mazonson; D L Patrick; A L Stewart; D P Buesching; S K Fifer
Journal:  J Gen Intern Med       Date:  1995-01       Impact factor: 5.128

7.  Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study.

Authors:  S Weyerer; H Dilling
Journal:  Sleep       Date:  1991-10       Impact factor: 5.849

8.  Biopsychobehavioral correlates of insomnia, V: Clinical characteristics and behavioral correlates.

Authors:  J D Kales; A Kales; E O Bixler; C R Soldatos; R J Cadieux; G J Kashurba; A Vela-Bueno
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112

  8 in total
  45 in total

1.  A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France.

Authors:  J Menzin; K M Lang; P Levy; E Levy
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

2.  Insomnia Symptoms Among Female Veterans: Prevalence, Risk Factors, and the Impact on Psychosocial Functioning and Health Care Utilization.

Authors:  Kimberly A Babson; Ava C Wong; Danielle Morabito; Rachel Kimerling
Journal:  J Clin Sleep Med       Date:  2018-06-15       Impact factor: 4.062

3.  Insomnia and depression.

Authors:  Daniel J Taylor
Journal:  Sleep       Date:  2008-04       Impact factor: 5.849

4.  Therapies for insomnia and comorbid chronic obstructive pulmonary disease with a focus on ramelteon (rozerem).

Authors:  Jack Greenberg; J B Goss
Journal:  P T       Date:  2009-09

5.  Shift Work and Sleep: Medical Implications and Management.

Authors:  Shazia Jehan; Ferdinand Zizi; Seithikurippu R Pandi-Perumal; Alyson K Myers; Evan Auguste; Girardin Jean-Louis; Samy I McFarlane
Journal:  Sleep Med Disord       Date:  2017-10-06

6.  Assessing depression symptoms in those with insomnia: an examination of the beck depression inventory second edition (BDI-II).

Authors:  Colleen E Carney; Christi Ulmer; Jack D Edinger; Andrew D Krystal; Faye Knauss
Journal:  J Psychiatr Res       Date:  2008-10-26       Impact factor: 4.791

7.  A Collaborative Paradigm for Improving Management of Sleep Disorders in Primary Care: A Randomized Clinical Trial.

Authors:  Jack D Edinger; Janet Grubber; Christi Ulmer; Jennifer Zervakis; Maren Olsen
Journal:  Sleep       Date:  2016-01-01       Impact factor: 5.849

Review 8.  Sleep disorders and quality of life in renal transplant recipients.

Authors:  Miklos Zsolt Molnar; Marta Novak; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

9.  Association of insomnia with quality of life, work productivity, and activity impairment.

Authors:  Susan C Bolge; Justin F Doan; Hema Kannan; Robert W Baran
Journal:  Qual Life Res       Date:  2009-03-14       Impact factor: 4.147

10.  Quality of life in nonorganic and organic sleep disorders: I. Comparison with normative data.

Authors:  Bernd Saletu; Wolfgang Prause; Henriette Löffler-Stastka; Peter Anderer; Nadja Brandstätter; Ali Zoghlami; Gerda Saletu-Zyhlarz; Heinz Katschnig
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.